Table 2.

Univariate analyses of factors associated with PFS and OS

Characteristic	Category	PFS		OS
		HR (95% CI)	P	HR (95% CI)	P
Gender	Male vs. female	1.31 (0.69–2.50)	0.412	0.74 (0.27–2.04)	0.554
Age	< 54 vs. ≥54 years	0.53 (0.26–1.06)	0.071	0.72 (0.26–2.04)	0.541
ECOG performance status	0–1 vs. 2–3	0.32 (0.16–0.63)	0.001	0.32 (0.11–0.94)	0.038
Primary site	Limbs vs. trunks vs. others	0.59 (0.31–1.12)	0.108	0.68 (0.25–1.89)	0.464
Metastasis organs	None/single vs. multiple organs	0.54 (0.26–1.12)	0.098	0.42 (0.12–1.48)	0.176
Lung metastasis	Yes vs. no	0.85 (0.44–1.66)	0.639	1.01 (0.34–2.95)	0.991
Liver metastasis	Yes vs. no	2.00 (0.74–5.36)	0.171	2.39 (0.67–8.52)	0.179
Bone metastasis	Yes vs. no	1.00 (0.52–1.95)	0.989	0.84 (0.30–2.38)	0.748
Treatment lines	1–2 vs. ≥3	0.47 (0.23–0.92)	0.028	0.30 (0.11–0.83)	0.022
Prior chemotherapy	Yes vs. no	2.00 (0.99–4.04)	0.055	4.42 (1.00-19.62)	0.051
Prior radiotherapy	Yes vs. no	2.02 (0.94–4.35)	0.074	2.24 (0.76–6.57)	0.142
Prior antiangiogenic therapy	Yes vs. no	1.13 (0.59–2.17)	0.713	0.84 (0.28–2.47)	0.746
Prior immunotherapy	Yes vs. no	1.10 (0.50–2.42)	0.806	0.36 (0.05–2.72)	0.319

Abbreviation: PFS: progression-free survival; OS: overall survival; HR: hazard ratio; CI: confidence interval; ECOG: Eastern Cooperative Oncology Group